Cristiana Gaiteiro

Cristiana Gaiteiro

Auto-generated profile, based on publicly available information

Cristiana Gaiteiro

Experimental Pathology and Therapeutics Group - Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Drug Resistance Updates
Verified
Journal Article
Closed access
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
APAndreia Peixoto
Andreia Peixoto
MNManuel Neves
Manuel Neves
CGCristiana Gaiteiro
Cristiana Gaiteiro
CRCelso Reis
Celso Reis
Lúcio Lara SantosLúcio Lara Santos
Lúcio Lara Santos

3 February 2016 in Scientific Reports
Verified
Journal Article
Open access
MAMobina Alemi
Mobina Alemi
CGCristiana Gaiteiro
Cristiana Gaiteiro
CRCarlos A Ribeiro
Carlos A Ribeiro
LSLuís Miguel Santos
Luís Miguel Santos
Joao R GomesJoao R Gomes
Joao R Gomes
ICIsabel Cardoso
Isabel Cardoso
Transthyretin (TTR) binds Aβ peptide, preventing its deposition and toxicity. TTR is decreased in Alzheimer’s disease (AD) patients. Additionally, AD transgenic mice with only one copy of the TTR gene show increased brain and plasma Aβ levels when compared to AD mice with both copies of the gene, suggesting TTR involvement in brain Aβ efflux and/or peripheral clearance. Here we showed that TTR promotes Aβ internalization and efflux in a human cerebral microvascular endothelial cell line, hCMEC/D3. TTR also stimulated brain-to-blood but not blood-to-brain Aβ permeability in hCMEC/D3, suggesting that TTR interacts directly with Aβ at the blood-brain-barrier. We also observed that TTR crosses the monolayer of cells only in the brain-to-blood direction, as confirmed by in vivo studies, suggesting that TTR can transport Aβ from, but not into the brain. Furthermore, TTR increased Aβ internalization by SAHep cells and by primary hepatocytes from TTR+/+ mice when compared to TTR−/− animals. We propose that TTR-mediated Aβ clearance is through LRP1, as lower receptor expression was found in brains and livers of TTR−/− mice and in cells incubated without TTR. Our results suggest that TTR acts as a carrier of Aβ at the blood-brain-barrier and liver, using LRP1.

1 February 2017 in Cancer Letters
Verified
Journal Article
Closed access
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
Ana MagalhaesAna Magalhaes
Ana Magalhaes
Joana GomesJoana Gomes
Joana Gomes
APAndreia Peixoto
Andreia Peixoto
CGCristiana Gaiteiro
Cristiana Gaiteiro
CRCelso Reis
Celso Reis

12 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
APAndreia Peixoto
Andreia Peixoto
Elisabete FernandesElisabete Fernandes
Elisabete Fernandes
CGCristiana Gaiteiro
Cristiana Gaiteiro
IPO-Porto LimaIPO-Porto Lima
IPO-Porto Lima
Rita AzevedoRita Azevedo
Rita Azevedo
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O -glycosylation extension Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension

16 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCCéu Costa
Céu Costa
SPSofia Pereira
Sofia Pereira
IPO-Porto LimaIPO-Porto Lima
IPO-Porto Lima
APAndreia Peixoto
Andreia Peixoto
Elisabete FernandesElisabete Fernandes
Elisabete Fernandes
Lúcio Lara SantosLúcio Lara Santos
Lúcio Lara Santos
Muscle invasive bladder cancer (MIBC, stage ≥T2) is generally associated with poor prognosis, constituting the second most common cause of death among genitourinary tumours. Due to high molecular heterogeneity significant variations in the natural history and disease outcome have been observed. This has also delayed the introduction of personalized therapeutics, making advanced stage bladder cancer almost an orphan disease in terms of treatment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen (STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are cancer-associated events that may hold potential for patient stratification and guided therapy. Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expression of Tn was residual and was not linked to stage or outcome, while STn was statically higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR pathway intermediates showed an equal distribution between non-muscle invasive bladder cancer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discriminating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Furthermore, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/mTOR pathway proteins in STn+ MIBC was independently associated with approximately 6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced bladder tumours mimicking the histological and molecular nature of human tumours were then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the number of invasive lesions and, concomitantly, the expression of STn and also pS6, the downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR pathway evaluation, holds potential to improve the stratification of stage disease. Animal experiments suggest that mTOR pathway inhibition could be a potential therapeutic approach for this specific subtype of MIBC.

1 October 2015 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
Gert FrickerGert Fricker
Gert Fricker
ICIsabel Cardoso
Isabel Cardoso
CRCarlos A Ribeiro
Carlos A Ribeiro
SRSandra Rocha
Sandra Rocha